The development of antagonists, chemical compounds, or other small molecules (i.e., small interfering (si)RNA) to neutralize VEGF has dramatically advanced the field of anti-angiogenic therapy and anti-VEGF therapy has now become widely used to treat angiogenesis-dependent disorders such as cancer and retinopathies like neovascular AMD [15], [16]. The gene discussed is VEGFA; the disease is cancer.